| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Laboratory of Experimental Chemotherapy and 2 Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
Requests for reprints: Michele Milella, Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. Phone: 39-06-5266-6919/6774; Fax: 39-06-5266-5637; E-mail: milella{at}ifo.it.
Mammalian target of rapamycin (mTOR) is increasingly recognized as a master regulator of fundamental cellular functions, whose deregulation may underlie neoplastic transformation and progression. Hence, mTOR has recently emerged as a promising target for therapeutic anticancer interventions in several human tumors, including breast cancer. Here, we investigated the antiangiogenic potential of temsirolimus (also known as CCI-779), a novel mTOR inhibitor currently in clinical development for the treatment of breast cancer and other solid tumors. Consistent with previous reports, sensitivity to temsirolimus-mediated growth inhibition varied widely among different breast cancer cell lines and was primarily due to inhibition of proliferation with little, if any, effect on apoptosis induction. In the HER-2 geneamplified breast cancer cell line BT474, temsirolimus inhibited vascular endothelial growth factor (VEGF) production in vitro under both normoxic and hypoxic conditions through inhibition of hypoxia-stimulated hypoxia-inducible factor (HIF)-1
expression and transcriptional activation. Interestingly, these effects were also observed in the MDA-MB-231 cell line, independent of its inherent sensitivity to the growth-inhibitory effects of temsirolimus. A central role for mTOR (and the critical regulator of cap-dependent protein translation, eIF4E) in the regulation of VEGF production by BT474 cells was further confirmed using a small interfering RNA approach to silence mTOR and eIF4E protein expression. In addition to its effect on HIF-1
mediated VEGF production, temsirolimus also directly inhibited serum- and/or VEGF-driven endothelial cell proliferation and morphogenesis in vitro and vessel formation in a Matrigel assay in vivo. Overall, these results suggest that antiangiogenic effects may substantially contribute to the antitumor activity observed with temsirolimus in breast cancer. (Cancer Res 2006; 66(11): 5549-54)
This article has been cited by other articles:
![]() |
T. B. Dorff, A. Goldkorn, and D. I. Quinn Review: Targeted therapy in renal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205. [Abstract] [PDF] |
||||
![]() |
S. L. Ellard, M. Clemons, K. A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, et al. Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 J. Clin. Oncol., September 20, 2009; 27(27): 4536 - 4541. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone Target-based therapies in breast cancer: current status and future perspectives Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yu, L. Toral-Barza, C. Shi, W.-G. Zhang, J. Lucas, B. Shor, J. Kim, J. Verheijen, K. Curran, D. J. Malwitz, et al. Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin Cancer Res., August 1, 2009; 69(15): 6232 - 6240. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ekshyyan, Y. Rong, X. Rong, K. M. Pattani, F. Abreo, G. Caldito, J. K. S. Chang, F. Ampil, J. Glass, and C.-A. O. Nathan Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma Mol. Cancer Ther., August 1, 2009; 8(8): 2255 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Brepoels, S. Stroobants, G. Verhoef, T. De Groot, L. Mortelmans, and C. De Wolf-Peeters 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model J. Nucl. Med., July 1, 2009; 50(7): 1102 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death Brain, June 1, 2009; 132(6): 1509 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marone, D. Erhart, A. C. Mertz, T. Bohnacker, C. Schnell, V. Cmiljanovic, F. Stauffer, C. Garcia-Echeverria, B. Giese, S.-M. Maira, et al. Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors Mol. Cancer Res., April 1, 2009; 7(4): 601 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Lane, J. M. Wood, P. M.J. McSheehy, P. R. Allegrini, A. Boulay, J. Brueggen, A. Littlewood-Evans, S.-M. Maira, G. Martiny-Baron, C. R. Schnell, et al. mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor Clin. Cancer Res., March 1, 2009; 15(5): 1612 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yu, J. Wang, Y. Chen, X. Wang, J. Pan, G. Li, Z. Jia, Q. Li, J. C. Yao, and K. Xie Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer Clin. Cancer Res., March 1, 2009; 15(5): 1821 - 1829. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Hartford, A. A. Desai, L. Janisch, T. Karrison, V. M. Rivera, L. Berk, J. W. Loewy, H. Kindler, W. M. Stadler, H. L. Knowles, et al. A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies Clin. Cancer Res., February 15, 2009; 15(4): 1428 - 1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Murphy, A. C. Spalding, Y. R. Somnay, S. Markwart, M. E. Ray, and D. A. Hamstra Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature Clin. Cancer Res., January 15, 2009; 15(2): 589 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ackler, Y. Xiao, M. J. Mitten, K. Foster, A. Oleksijew, M. Refici, S. Schlessinger, B. Wang, S. R. Chemburkar, J. Bauch, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol. Cancer Ther., October 1, 2008; 7(10): 3265 - 3274. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies Oncologist, October 1, 2008; 13(10): 1084 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Yao, A. T. Phan, D. Z. Chang, R. A. Wolff, K. Hess, S. Gupta, C. Jacobs, J. E. Mares, A. N. Landgraf, A. Rashid, et al. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study J. Clin. Oncol., September 10, 2008; 26(26): 4311 - 4318. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features Ann. Onc., August 1, 2008; 19(8): 1387 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Garcia and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Jiang, H. Kenerson, L. Aicher, R. Miyaoka, J. Eary, J. Bissler, and R. S. Yeung The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake Am. J. Pathol., June 1, 2008; 172(6): 1748 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Shor, W.-G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, and K. Yu A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis Cancer Res., April 15, 2008; 68(8): 2934 - 2943. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Boni, C. Leister, J. Burns, M. Cincotta, B. Hug, and L. Moore Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450-Inducing Medications J. Clin. Pharmacol., November 1, 2007; 47(11): 1430 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Motzer, G. R. Hudes, B. D. Curti, D. F. McDermott, B. J. Escudier, S. Negrier, B. Duclos, L. Moore, T. O'Toole, J. P. Boni, et al. Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma J. Clin. Oncol., September 1, 2007; 25(25): 3958 - 3964. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Mosley, J. T. Poirier, D. D. Seachrist, M. D. Landis, and R. A. Keri Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer Mol. Cancer Ther., August 1, 2007; 6(8): 2188 - 2197. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |